d(GC) - Association of Biotechnology and Pharmacy

Current Trends in Biotechnology and Pharmacy
Vol. 6 (2) 119-144 April 2012, ISSN 0973-8916 (Print), 2230-7303 (Online)
A.H., Pugh, T.J., Wilkinson, J., Fisher, S.,
Winckler, W., Mahan, S., Ardlie, K.,
Baldwin, J., Simons, J.W., Kitabayashi, N.,
MacDonald, T.Y., Kantoff, P.W., Chin, L.,
Gabriel, S.B., Gerstein, M.B., Golub, T.R.,
Meyerson, M., Tewari, A., Lander, E.S.,
Getz, G., Rubin, M.A., and Garraway, L.A.
(2011). The genomic complexity of primary
human prostate cancer. Nature, 470: 214-
20.
18. Sreenath, T.L., Dobi, A., Petrovics, G., and
Srivastava, S. (2011). Oncogenic activation
of ERG: A predominant mechanism in
prostate cancer. J Carcinog, 10: 37.
19. Tan, S.H., Petrovics, G., and Srivastava, S.
(2011). Highlights from the prostate cancer
genome report. Asian J Androl, 13: 659-60.
20. Dunn, T.A., Fedor, H.L., De Marzo, A.M.,
and Luo, J. (2012). Molecular profiling of
indolent human prostate cancer: tackling
technical challenges to achieve high-fidelity
genome-wide data. Asian J Androl, Epub
ahead of print.
21. Travis, W., Brambilla, E., Muller-Hermeling,
K., and Harris, C.C. (2000). World Health
Organization Classification of Tumours.
Pathology and Genetics of Tumours of the
Lung, Pleura, Thymus and Heart., IARC
Press, Lyon, France, pp. 9-124.
22. Martin, P., Kelly, C.M., and Carney, D.
(2006). Epidermal growth factor receptortargeted
agents for lung cancer. Cancer
Control, 13: 129-40.
23. Travis, W.D., Travis, L.B., and Devesa, S.S.
(1995). Lung cancer. Cancer, 75: 191-202.
24. Petersen, I. (2010). The morphological and
molecular diagnosis of lung cancer. Dtsch
Arztebl Int, 108: 525-31.
25. Adamo, V., Franchina, T., Adamo, B.,
Denaro, N., Gambadauro, P., Chiofalo, G.,
Scimone, A., Caristi, N., Russo, A., and
Giordano, A. (2009). Gefitinib in lung cancer
therapy: clinical results, predictive markers
Developing world personalized cancer medicine
137
of response and future perspectives.
Cancer Biol Ther, 8: 206-12.
26. Lynch, T.J., Bell, D.W., Sordella, R.,
Gurubhagavatula, S., Okimoto, R.A.,
Brannigan, B.W., Harris, P.L., Haserlat,
S.M., Supko, J.G., Haluska, F.G., Louis,
D.N., Christiani, D.C., Settleman, J., and
Haber, D.A. (2004). Activating mutations in
the epidermal growth factor receptor
underlying responsiveness of non-smallcell
lung cancer to gefitinib. N Engl J Med,
350: 2129-39.
27. Paez, J.G., Janne, P.A., Lee, J.C., Tracy,
S., Greulich, H., Gabriel, S., Herman, P.,
Kaye, F.J., Lindeman, N., Boggon, T.J.,
Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J.,
Sellers, W.R., Johnson, B.E., and
Meyerson, M. (2004). EGFR mutations in
lung cancer: correlation with clinical
response to gefitinib therapy. Science, 304:
1497-500.
28. Zhang, X. and Chang, A. (2007). Somatic
mutations of the epidermal growth factor
receptor and non-small-cell lung cancer. J
Med Genet, 44: 166-72.
29. Mok, T.S. (2011). Personalized medicine in
lung cancer: what we need to know. Nat
Rev Clin Oncol, 8: 661-8.
30. Rosell, R., Moran, T., Queralt, C., Porta, R.,
Cardenal, F., Camps, C., Majem, M., Lopez-
Vivanco, G., Isla, D., Provencio, M., Insa,
A., Massuti, B., Gonzalez-Larriba, J.L., Paz-
Ares, L., Bover, I., Garcia-Campelo, R.,
Moreno, M.A., Catot, S., Rolfo, C., Reguart,
N., Palmero, R., Sanchez, J.M., Bastus, R.,
Mayo, C., Bertran-Alamillo, J., Molina, M.A.,
Sanchez, J.J., and Taron, M. (2009).
Screening for epidermal growth factor
receptor mutations in lung cancer. N Engl
J Med, 361: 958-67.
31. Shigematsu, H. and Gazdar, A.F. (2004).
Mutations of EGFR in lung cancers and
their implications for targeted therapy.
Discov Med, 4: 444-7.